

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

RIGEL PHARMACEUTICALS, INC.,

Petitioner,

v.

SERVIER PHARMACEUTICALS LLC

Patent Owner.

Case IPR2022-01423
U.S. Patent No. 10,610,125

**JOINT REQUEST TO TREAT EXHIBITS 1059 AND 1060
AS BUSINESS CONFIDENTIAL INFORMATION**

The Parties have jointly filed a motion to terminate this proceeding pursuant to a settlement agreement between the Parties. Pursuant to the Board's request as set forth in its email of December 19, 2022 and in accordance with 35 U.S.C. §317(b), the Parties have filed the settlement agreements as Exhibits 1059 and 1060. The settlement agreements provide that the terms of the agreement are to be maintained as confidential by the Parties and, subject to certain exceptions, may not be disclosed to any third parties without the express written consent of the non-disclosing party.

The Board has granted the Parties leave to file this motion to treat the settlement agreements as business confidential information. The Parties therefore jointly move pursuant to 37 C.F.R. § 42.74(c) that the settlement agreements, submitted as Exhibits 1059 and 1060, be treated as business confidential information and be kept separate from the files of the patent at issue in this proceeding.

Date: December 27, 2022

Respectfully submitted,

By: /James L. Lovsin/

James L. Lovsin, Reg. No. 69,550

lovsin@mbhb.com

McDONNELL BOEHNEN

HULBERT & BERGHOFF LLP

300 S. Wacker Drive

Chicago, IL 60606

312-913-0001

Counsel for Petitioner

Rigel Pharmaceuticals, Inc.

/William M. Fink/

William M. Fink, Reg. No. 72,332

tfink@omm.com

O'MELVENY & MYERS LLP

1625 I Street NW

Washington D.C. 20006

(202) 383-5300

Counsel for Patent Owner

Servier Pharmaceuticals LLC